| 2026-08-18 | Press release | Halozyme Appoints Dannielle Appelhans to its Board of Directors |
| 2026-08-06 | Press release | HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE |
| 2026-07-23 | Press release | Halozyme to Report Second Quarter 2026 Financial and Operating Results |
| 2026-07-20 | Press release | Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous For |
| 2026-06-30 | Press release | Halozyme Appoints David Ramsay as President Drug Delivery |
| 2026-06-15 | Press release | Halozyme Statement on Proposed Rule for IPAY 2029 |
| 2026-06-15 | Press release | Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Dr |
| 2026-05-11 | Press release | HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE |
| 2026-05-11 | Earnings deck | Presentation
of Q1 2026, PDF file, (opens in new window) |
| 2026-05-11 | Press release | Press Release
of Q1 2026, PDF file, (opens in new window) |
| 2026-05-07 | Press release | Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple |
| 2026-05-06 | Press release | Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology |
| 2026-04-30 | Press release | Halozyme to Report First Quarter 2026 Financial and Operating Results |
| 2026-04-30 | Press release | Halozyme Appoints Darren Snellgrove as Chief Financial Officer |
| 2026-04-07 | Press release | Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology |
| 2026-03-12 | Press release | Halozyme Appoints David Ramsay as Interim Chief Financial Officer |
| 2026-03-06 | Press release | U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma |
| 2026-02-25 | Press release | Halozyme to Participate in Upcoming Investor Conferences |
| 2026-02-17 | Press release | HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE |
| 2026-02-17 | Press release | Halozyme 4Q and FY 2025 Financial and Operating Results Conference Call |
| 2026-02-17 | Earnings deck | Presentation |
| 2026-02-10 | Press release | Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results |
| 2026-01-28 | Presentation | Investor Conference Call |
| 2026-01-28 | Press release | Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance |
| 2026-01-20 | Press release | Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update |
| 2026-01-10 | ESG report | Climate Risk Report |
| 2026-01-08 | Press release | Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with |
| 2026-01-05 | Press release | Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated wit |
| 2025-10-01 | Presentation | Halozyme Investor Call |
| 2024-05-07 | Earnings deck | Presentation |
| 2024-03-19 | Annual report | 2022 Annual Report of 2022 Annual Report, PDF file, (opens in new window) |
| 2023-02-21 | Earnings deck | Presentation |
| 2022-03-17 | Annual report | 2021 Annual Report of 2021 Annual Report, PDF file, (opens in new window) |
| Annual report | 2014 Annual Report of 2014 Annual Report, PDF file, (opens in new window) |
| Annual report | 2015 Annual Report of 2015 Annual Report, PDF file, (opens in new window) |